Document Detail

Targeting EGFR and IGF 1R: a promising combination therapy for metastatic cancer .
MedLine Citation:
PMID:  23277048     Owner:  NLM     Status:  In-Data-Review    
Acute drug resistance, intolerable side effects and non-specific target activation are the crucial barriers for efficient translational outcome of target directed cancer drug discovery. In the last five years, many of the bull's eye drugs failed to obtain FDA approval because of highly complicated mechanisms of the targeting receptors. These receptors include epidermal growth factor receptor (EGFR) and Insulin-like growth factor receptor 1 (IGF 1R), and are considered as pivotal signaling routes in highly transformed metastatic cancers. IGF 1R and EGFR families show homology in their structure and both the receptors share considerable crosstalk in their functions. An aberrant activation of these two pathways is often diagnosed among many cancer patients. Therefore, target based monoclonal antibodies and small molecule tyrosine kinase inhibitors, either in combination or co-targeting these two receptors may provide a new era of promising therapy and can help in remarkable progress among cancer patients.
Inderpal Singh; Hina Amin; Bilal Rah; Anindya Goswami
Related Documents :
23326338 - Leuprorelin acetate long-lasting effects on gnrh receptors of prostate cancer cells: an...
528998 - Comparison of dopamine synthesis regulation in the terminals of nigrostriatal, mesolimb...
8592158 - Increased neostriatal tyrosine hydroxylation during stress: role of extracellular dopam...
3220118 - Repeated administration of ha-966 and haloperidol to rats: similar tolerance to striata...
15661568 - Adenosine receptor mediates nicotine-induced antinociception in formalin test.
10361258 - The igf axis and programmed cell death.
Publication Detail:
Type:  Journal Article     Date:  2013-01-01
Journal Detail:
Title:  Frontiers in bioscience (Scholar edition)     Volume:  5     ISSN:  1945-0524     ISO Abbreviation:  Front Biosci (Schol Ed)     Publication Date:  2013  
Date Detail:
Created Date:  2013-01-01     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101485241     Medline TA:  Front Biosci (Schol Ed)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  231-46     Citation Subset:  IM    
Cancer Pharmacology Division, Indian Institute of Integrative Medicine (CSIR), Jammu Tawi, 180001, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cellular basis of hepatic fibrosis and its role in inflammation and cancer .
Next Document:  Vitamin D3: an ever green molecule .